Clinical Trial Update: N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating inebilizumab for Neuromyelitis Optica Spectrum Disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Inebilizumab (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-12-26